Barac Ramona Ileana, Harghel Vasile, Anton Nicoleta, Baltă George, Tofolean Ioana Teodora, Dragosloveanu Christiana, Leuștean Laurențiu Flavius, Deleanu Dan George, Barac Diana Andreea
Department of Ophthalmology, "Carol Davila" University of Medicine and Pharmacy, 050474 București, Romania.
Department of Ophthalmology, University of Medicine and Pharmacy "Grigore T. Popa", 700115 Iași, Romania.
Bioengineering (Basel). 2024 Aug 12;11(8):820. doi: 10.3390/bioengineering11080820.
Glaucoma is a leading cause of irreversible blindness worldwide and is particularly challenging to treat in its refractory forms. The Ahmed valve offers a potential solution for these difficult cases. This research aims to assess the initial clinical experience with Ahmed valve implantation in Romania, evaluating its effectiveness, associated complications, and overall patient outcomes over a five-year period.
We conducted a prospective study on 50 patients who underwent Ahmed valve implantation due to various types of glaucoma. Patients were monitored at several intervals, up to five years post-surgery. Intraocular pressure and visual acuity were the primary measures of success.
On average, patients maintained the intraocular pressure within the targeted range, with the mean intraocular pressure being 17 mmHg 5 years post-surgery. Success, defined as maintaining target intraocular pressure without additional surgery, was achieved in 82% at 1 year, 68% at 3 years, and 60% after 5 years postoperative.
Ahmed valve implantation is a viable treatment option for refractory glaucoma, demonstrating significant intraocular pressure reduction and manageable complication rates over a five-year follow-up period. Future research should focus on long-term outcomes and optimization of surgical techniques to further reduce complication rates and improve patient quality of life.
青光眼是全球不可逆性失明的主要原因,其难治性形式的治疗尤其具有挑战性。艾哈迈德瓣膜为这些疑难病例提供了一种潜在的解决方案。本研究旨在评估罗马尼亚艾哈迈德瓣膜植入术的初步临床经验,评估其在五年期间的有效性、相关并发症及总体患者预后。
我们对50例因各种类型青光眼接受艾哈迈德瓣膜植入术的患者进行了一项前瞻性研究。对患者进行了多次随访,直至术后五年。眼压和视力是成功的主要衡量指标。
平均而言,患者的眼压维持在目标范围内,术后5年平均眼压为17 mmHg。成功定义为无需额外手术即可维持目标眼压,术后1年成功率为82%,3年为68%,5年为60%。
艾哈迈德瓣膜植入术是难治性青光眼的一种可行治疗选择,在五年的随访期内显示出显著的眼压降低和可控的并发症发生率。未来的研究应关注长期预后以及手术技术的优化,以进一步降低并发症发生率并改善患者生活质量。